BIOMAT Database Logo BIOMAT Database Logo

Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. 1991

S L McElroy, and E C Dessain, and H G Pope, and J O Cole, and P E Keck, and F R Frankenberg, and H G Aizley, and S O'Brien
Biological Psychiatry Program, University of Cincinnati College of Medicine, OH 45267-0559.

BACKGROUND Although growing research indicates that the atypical antipsychotic agent clozapine is effective in patients with schizophrenia, little is known about the efficacy of clozapine in patients with schizoaffective disorder or psychotic mood disorders. The purpose of this study was to assess whether or not clozapine is effective in some patients with schizoaffective disorder or psychotic mood disorders. METHODS By surveying treating clinicians and chart data, we assessed treatment response in 85 consecutive patients, including 39 with schizophrenia, 25 with schizoaffective disorder, and 14 with bipolar disorder with psychotic features, who received clozapine for at least 6 weeks at our center. RESULTS All patients were either inadequately responsive to or unable to tolerate standard somatic therapies. Compared to patients with schizophrenia, patients with schizoaffective disorder and bipolar disorder with psychotic features displayed significantly higher response rates to clozapine. CONCLUSIONS Clozapine may be a useful drug in the treatment of patients with schizoaffective disorder or psychotic mood disorders who are treatment resistant or intolerant of side effects.

UI MeSH Term Description Entries
D008297 Male Males
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D011618 Psychotic Disorders Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994) Psychoses,Psychosis, Brief Reactive,Schizoaffective Disorder,Schizophreniform Disorders,Psychosis,Brief Reactive Psychoses,Brief Reactive Psychosis,Disorder, Psychotic,Disorder, Schizoaffective,Disorder, Schizophreniform,Disorders, Psychotic,Disorders, Schizoaffective,Disorders, Schizophreniform,Psychoses, Brief Reactive,Psychotic Disorder,Reactive Psychoses, Brief,Reactive Psychosis, Brief,Schizoaffective Disorders,Schizophreniform Disorder
D003024 Clozapine A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. Clozaril,Leponex
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001714 Bipolar Disorder A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence. Affective Psychosis, Bipolar,Bipolar Disorder Type 1,Bipolar Disorder Type 2,Bipolar Mood Disorder,Depression, Bipolar,Manic Depression,Manic Disorder,Manic-Depressive Psychosis,Psychosis, Manic-Depressive,Type 1 Bipolar Disorder,Type 2 Bipolar Disorder,Psychoses, Manic-Depressive,Bipolar Affective Psychosis,Bipolar Depression,Bipolar Disorders,Bipolar Mood Disorders,Depression, Manic,Depressions, Manic,Disorder, Bipolar,Disorder, Bipolar Mood,Disorder, Manic,Manic Depressive Psychosis,Manic Disorders,Mood Disorder, Bipolar,Psychoses, Bipolar Affective,Psychoses, Manic Depressive,Psychosis, Bipolar Affective,Psychosis, Manic Depressive
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder

Related Publications

S L McElroy, and E C Dessain, and H G Pope, and J O Cole, and P E Keck, and F R Frankenberg, and H G Aizley, and S O'Brien
Insight into illness in schizophrenia, schizoaffective disorder, and mood disorders with psychotic features.
January 2001, The American journal of psychiatry,
S L McElroy, and E C Dessain, and H G Pope, and J O Cole, and P E Keck, and F R Frankenberg, and H G Aizley, and S O'Brien
Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders.
October 1995, The Journal of clinical psychiatry,
S L McElroy, and E C Dessain, and H G Pope, and J O Cole, and P E Keck, and F R Frankenberg, and H G Aizley, and S O'Brien
Mood disorder with psychotic features, schizoaffective disorder, and schizophrenia with mood features: trouble at the borders.
February 2005, International review of psychiatry (Abingdon, England),
S L McElroy, and E C Dessain, and H G Pope, and J O Cole, and P E Keck, and F R Frankenberg, and H G Aizley, and S O'Brien
Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study.
May 2000, The Journal of clinical psychiatry,
S L McElroy, and E C Dessain, and H G Pope, and J O Cole, and P E Keck, and F R Frankenberg, and H G Aizley, and S O'Brien
Schizoaffective disorders are psychotic mood disorders; there are no schizoaffective disorders.
August 2006, Psychiatry research,
S L McElroy, and E C Dessain, and H G Pope, and J O Cole, and P E Keck, and F R Frankenberg, and H G Aizley, and S O'Brien
Combined clozapine-lithium treatment for schizophrenia and schizoaffective disorder.
January 1998, European psychiatry : the journal of the Association of European Psychiatrists,
S L McElroy, and E C Dessain, and H G Pope, and J O Cole, and P E Keck, and F R Frankenberg, and H G Aizley, and S O'Brien
Schizoaffective and mood-incongruent psychotic affective disorders.
March 1994, The American journal of psychiatry,
S L McElroy, and E C Dessain, and H G Pope, and J O Cole, and P E Keck, and F R Frankenberg, and H G Aizley, and S O'Brien
Treatment of schizoaffective disorder and schizophrenia with mood symptoms.
August 1999, The American journal of psychiatry,
S L McElroy, and E C Dessain, and H G Pope, and J O Cole, and P E Keck, and F R Frankenberg, and H G Aizley, and S O'Brien
Ten-year outcome: patients with schizoaffective disorders, schizophrenia, affective disorders and mood-incongruent psychotic symptoms.
November 2000, The British journal of psychiatry : the journal of mental science,
S L McElroy, and E C Dessain, and H G Pope, and J O Cole, and P E Keck, and F R Frankenberg, and H G Aizley, and S O'Brien
Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study.
April 2003, The Journal of clinical psychiatry,
Copied contents to your clipboard!